» Articles » PMID: 23554908

Functional Implications of MicroRNA-215 in TGF-β1-induced Phenotypic Transition of Mesangial Cells by Targeting CTNNBIP1

Overview
Journal PLoS One
Date 2013 Apr 5
PMID 23554908
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Mesangial cell (MC) phenotypic transition is crucial for the progression of diabetic nephropathy. A major stimulus mediating high glucose-induced MC phenotypic transition is TGF-β1. Our current study focuses on microRNA-215 (miR-215) and investigates its role in TGF-β1-mediated MC phenotypic transition. Using real-time quantitative PCR (qRT-PCR) and northern blotting, we determined that the miR-192/215 family is dramatically upregulated under diabetic conditions both in vitro and in vivo. Gain- and loss-of-function approaches demonstrated that miR-215 inhibition significantly inhibited TGF-β1-induced mouse mesangial cell (MMC) phenotypic transition, whereas miR-215 upregulation promoted MMC phenotypic transition. Interestingly, these changes were not detected in cells that were treated with TGF-β1 and miR-192 mimics or inhibitors. These results suggest that miR-215 participates in TGF-β1-induced MMC phenotypic transition. Luciferase reporter assays were used to identify whether catenin-beta interacting protein 1 (CTNNBIP1) is a direct target of miR-215, which was predicted by bioinformatic analysis. Mechanistic studies revealed that CTNNBIP1 suppresses Wnt/β-catenin signaling and that miR-215 promotes β-catenin activation and upregulates α-SMA and fibronectin expression in TGF-β1-treated MMCs by targeting CTNNBIP1. In addition, in vivo miR-215 silencing with a specific antagomir significantly increased CTNNBIP1 protein expression, resulting in reduced β-catenin activity and decreased α-SMA and fibronectin expression in db/db mouse kidney glomeruli. Taken together, our findings indicate that miR-215 plays an essential role in MC phenotypic transition by regulating the CTNNBIP1/β-catenin pathway, which is related to the pathogenesis of diabetic nephropathy.

Citing Articles

Incretin-based therapy: a new horizon in diabetes management.

Zarei M, Sahebi Vaighan N, Farjoo M, Talebi S, Zarei M J Diabetes Metab Disord. 2024; 23(2):1665-1686.

PMID: 39610543 PMC: 11599551. DOI: 10.1007/s40200-024-01479-3.


Roles of microRNA-192 in diabetic nephropathy: the clinical applications and mechanisms of action.

Wan X, Liao J, Lai H, Zhang S, Cui J, Chen C Front Endocrinol (Lausanne). 2023; 14:1179161.

PMID: 37396169 PMC: 10309560. DOI: 10.3389/fendo.2023.1179161.


The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy.

Szostak J, Goracy A, Durys D, Dec P, Modrzejewski A, Pawlik A Int J Mol Sci. 2023; 24(7).

PMID: 37047185 PMC: 10094215. DOI: 10.3390/ijms24076214.


Molecular profiling of urinary extracellular vesicles in chronic kidney disease and renal fibrosis.

Tepus M, Tonoli E, Verderio E Front Pharmacol. 2023; 13:1041327.

PMID: 36712680 PMC: 9877239. DOI: 10.3389/fphar.2022.1041327.


Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease.

Yan Z, Wang G, Shi X Front Pharmacol. 2022; 12:785375.

PMID: 34992536 PMC: 8724575. DOI: 10.3389/fphar.2021.785375.


References
1.
Daniels D, Weis W . ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell. 2002; 10(3):573-84. DOI: 10.1016/s1097-2765(02)00631-7. View

2.
Lussier C, Brial F, Roy S, Langlois M, Verdu E, Rivard N . Loss of hepatocyte-nuclear-factor-1alpha impacts on adult mouse intestinal epithelial cell growth and cell lineages differentiation. PLoS One. 2010; 5(8):e12378. PMC: 2927538. DOI: 10.1371/journal.pone.0012378. View

3.
Mishra R, Cool B, Laderoute K, Foretz M, Viollet B, Simonson M . AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem. 2008; 283(16):10461-9. DOI: 10.1074/jbc.M800902200. View

4.
Herrera G . Plasticity of mesangial cells: a basis for understanding pathological alterations. Ultrastruct Pathol. 2006; 30(6):471-9. DOI: 10.1080/01913120600932594. View

5.
Ziyadeh F . Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol. 2003; 15 Suppl 1:S55-7. DOI: 10.1097/01.asn.0000093460.24823.5b. View